Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis

Company Overview

Dr. Reddy’s Laboratories Limited is a Hyderabad, India-based pharmaceutical company that develops, manufactures and markets medicines. Its portfolio includes generic pharmaceuticals, active pharmaceutical ingredients (APIs), biosimilars and proprietary products, as well as over-the-counter and consumer health offerings in selected markets.

Founded in 1984 by Dr. Kallam Anji Reddy, the company began with a focus on APIs and expanded into finished-dose medicines and international pharmaceutical markets. Dr. Reddy’s products span therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology.

Dr. Reddy’s serves patients and healthcare providers in India, the United States, Europe and other emerging markets. The company operates through research and development, manufacturing and commercial operations across multiple regions. G. V. Prasad serves as co-chairman and managing director, while Erez Israeli serves as chief executive officer.

Key Stats

• Today's Range: $12.14 to $12.26
• 50-Day Range: $11.37 to $12.94
• 52-Week Range: $11.36 to $15.67
• Volume: 1.89 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $10.18 billion
• P/E Ratio: 27.71
• Dividend Yield: 0.49%
• Price Target: N/A
• Consensus Rating: Reduce

Dr. Reddy's Laboratories Stock Analysis - MarketRank™

Dr. Reddy's Laboratories scored higher than 33% of companies evaluated by MarketBeat, and ranked 719th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Dr. Reddy's Laboratories has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Dr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 26.67%

Earnings Growth

Earnings for Dr. Reddy's Laboratories are expected to grow by 26.67% in the coming year, from $0.45 to $0.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dr. Reddy's Laboratories is 27.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dr. Reddy's Laboratories is 27.71, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.48.

Price to Earnings Growth Ratio

Dr. Reddy's Laboratories has a PEG Ratio of 2.54. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Dr. Reddy's Laboratories has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.92% of the float of Dr. Reddy's Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 11.02, which indicates bearish sentiment.

Change versus previous month

Short interest in Dr. Reddy's Laboratories has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Dr. Reddy's Laboratories has a dividend yield of 0.53%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Dr. Reddy's Laboratories does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Dr. Reddy's Laboratories is 13.64%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.53% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Dr. Reddy's Laboratories has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.

Percentage Held by Institutions

3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.

Company Calendar

• Last Earnings: 7/23/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 10/23/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:RDY
• CIK: 1135951
• Web: www.drreddys.com
• Phone: 914049002900
• Fax: 91-40-4900-2999
• Employees: 27,527
• Year Founded: 1984

Profitability

• EPS (Trailing Twelve Months): $0.44
• Trailing P/E Ratio: 27.71
• Forward P/E Ratio: 27.10
• P/E Growth: 2.54
• Net Income: $456 million
• Net Margins: 10.15%
• Pretax Margin: 11.58%
• Return on Equity: 9.49%
• Return on Assets: 6.32%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 1.90
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $3.58 billion
• Price / Sales: 2.84
• Cash Flow: $0.85 per share
• Price / Cash Flow: 14.39
• Book Value: $4.86 per share
• Price / Book: 2.51

Miscellaneous

• Outstanding Shares: 834,670,000
• Free Float: 817,978,000
• Market Cap: $10.18 billion
• Optionable: Optionable
• Beta: 0.28